<p>美国最高法院拒绝审理 <strong>礼来公司</strong> 的上诉，维持了一项与药品制造商因错误报告药品定价数据而导致的医疗补助回扣不足的 194 百万美元举报者判决。</p>
<p><strong>• 礼来股票正在下跌。为什么 LLY 股票交易下跌？</strong></p>
<p>彭博社周一的报道指出，法官们在没有评论的情况下作出了这一决定，驳回了礼来对联邦虚假索赔法的更广泛宪法挑战。</p>
<p>该公司辩称，该法律不当允许私人个人代表政府提起诉讼，并获得任何财务回收的一部分。</p>
<p>根据司法部在上诉中引用的数据，举报者在 2024 财年提起了创纪录的 979 起虚假索赔法诉讼，而和解和判决总额超过 29 亿美元。</p>
<p><strong>另请阅读：这款减肥药挑战者可能会遵循礼来的商业模式：分析师</strong></p>
<h2><strong>举报者指控医疗补助回扣不足</strong></h2>
<p>争议源于制药公司必须向州项目提供的医疗补助药品回扣计算。</p>
<p>举报者罗纳德·斯特雷克指控礼来低估了从批发商获得的收入，这 allegedly 减少了医疗补助项目应支付的回扣约 6100 万美元。</p>
<p>芝加哥的一名联邦陪审团最终裁定礼来承担责任，导致 194 百万美元的赔偿。</p>
<p>报告补充说，礼来在上诉期间辩称，斯特雷克多年来一直在追求类似的制药定价案件，并将其描述为 “私人赏金猎人”。</p>
<p>该公司还坚持认为，其定价方法反映了行业普遍做法，之前在涉及同一举报者的另一案件中得到了四位联邦法官的支持。</p>
<h2><strong>保守派法官之前质疑虚假索赔法</strong></h2>
<p>斯特雷克敦促最高法院驳回礼来的请愿，认为没有理由让法院重新审视陪审团的裁决或重新评估在审判中已经权衡的证据。</p>
<p>司法部拒绝介入此案，允许斯特雷克根据虚假索赔法的条款独立进行诉讼，该条款允许私人举报者提起诉讼。</p>
<p><strong>LLY 价格动态：</strong> 根据 Benzinga Pro 的数据显示，礼来（LLY）股票在周一发布时下跌了 1.64%，报 988.42 美元。</p>
<p>在过去一个月中，礼来（LLY）股票上涨了约 6.6%，而标准普尔 500 指数上涨了 3.8%，与年初至今该股票下跌约 8% 相比，指数上涨了 7.3%。</p>
<p><em>照片：Jonathan Weiss / Shutterstock</em></p>
<p><strong>另请阅读：Ondas 在 Omnisys 收购中大举押注 AI 战场软件</strong></p>

礼来

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - Vanguard

<p>美国最高法院驳回了礼来的上诉，涉及一项 194 百万美元的举报者判决，因其通过错误报告药品定价而未能支付医疗补助回扣。该决定维护了联邦虚假索赔法，允许个人代表政府提起诉讼。裁决后，礼来的股票下跌了 1.64%，至 988.42 美元，公司辩称举报者的指控毫无根据，其定价做法符合行业标准</p>

<p>The U.S. Supreme Court declined to hear an appeal from <strong>Eli Lilly &amp; Co.</strong>, leaving in place a $194 million whistleblower judgment tied to allegations that the drugmaker underpaid Medicaid rebates by misreporting drug pricing data.</p>
<div class="lb-trans"><p>美国最高法院拒绝审理 <strong>礼来公司</strong> 的上诉，维持了一项与药品制造商因错误报告药品定价数据而导致的医疗补助回扣不足的 194 百万美元举报者判决。</p>
</div><p><strong>• Eli Lilly stock is trending lower. Why is LLY stock trading lower?</strong></p>
<div class="lb-trans"><p><strong>• 礼来股票正在下跌。为什么 LLY 股票交易下跌？</strong></p>
</div><p>The Bloomberg report on Monday noted that the justices issued the decision without comment, rejecting Lilly's broader constitutional challenge to the federal False Claims Act.</p>
<div class="lb-trans"><p>彭博社周一的报道指出，法官们在没有评论的情况下作出了这一决定，驳回了礼来对联邦虚假索赔法的更广泛宪法挑战。</p>
</div><p>The company argued the law improperly allows private individuals to sue on behalf of the government and receive a portion of any financial recovery.</p>
<div class="lb-trans"><p>该公司辩称，该法律不当允许私人个人代表政府提起诉讼，并获得任何财务回收的一部分。</p>
</div><p>According to Department of Justice data cited in the appeal, whistleblowers filed a record 979 False Claims Act lawsuits in fiscal 2024, while settlements and judgments topped $2.9 billion.</p>
<div class="lb-trans"><p>根据司法部在上诉中引用的数据，举报者在 2024 财年提起了创纪录的 979 起虚假索赔法诉讼，而和解和判决总额超过 29 亿美元。</p>
</div><p><strong>Read Also: This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst</strong></p>
<div class="lb-trans"><p><strong>另请阅读：这款减肥药挑战者可能会遵循礼来的商业模式：分析师</strong></p>
</div><h2><strong>Whistleblower Alleged Medicaid Rebate Underpayments</strong></h2>
<div class="lb-trans"><h2><strong>举报者指控医疗补助回扣不足</strong></h2>
</div><p>The dispute stemmed from Medicaid drug rebate calculations that pharmaceutical companies must provide to state programs.</p>
<div class="lb-trans"><p>争议源于制药公司必须向州项目提供的医疗补助药品回扣计算。</p>
</div><p>Whistleblower Ronald Streck accused Lilly of understating revenue received from wholesalers, which allegedly reduced rebate payments owed to Medicaid programs by roughly $61 million.</p>
<div class="lb-trans"><p>举报者罗纳德·斯特雷克指控礼来低估了从批发商获得的收入，这 allegedly 减少了医疗补助项目应支付的回扣约 6100 万美元。</p>
</div><p>A federal jury in Chicago ultimately found Lilly liable, resulting in the $194 million award.</p>
<div class="lb-trans"><p>芝加哥的一名联邦陪审团最终裁定礼来承担责任，导致 194 百万美元的赔偿。</p>
</div><p>The report added that Lilly argued during the appeal that Streck had pursued similar pharmaceutical pricing cases for years and described him as a &#34;private bounty hunter.&#34;</p>
<div class="lb-trans"><p>报告补充说，礼来在上诉期间辩称，斯特雷克多年来一直在追求类似的制药定价案件，并将其描述为 “私人赏金猎人”。</p>
</div><p>The company also maintained that its pricing approach reflected a common industry practice that had previously been upheld by four federal judges in a separate case involving the same whistleblower.</p>
<div class="lb-trans"><p>该公司还坚持认为，其定价方法反映了行业普遍做法，之前在涉及同一举报者的另一案件中得到了四位联邦法官的支持。</p>
</div><h2><strong>Conservative Justices Previously Questioned False Claims Act</strong></h2>
<div class="lb-trans"><h2><strong>保守派法官之前质疑虚假索赔法</strong></h2>
</div><p>Streck urged the Supreme Court to reject Lilly's petition, arguing there was no reason for the court to revisit the jury's findings or reassess evidence already weighed during trial.</p>
<div class="lb-trans"><p>斯特雷克敦促最高法院驳回礼来的请愿，认为没有理由让法院重新审视陪审团的裁决或重新评估在审判中已经权衡的证据。</p>
</div><p>The Department of Justice declined to intervene in the case, leaving Streck to litigate independently under provisions of the False Claims Act that permit private whistleblower suits.</p>
<div class="lb-trans"><p>司法部拒绝介入此案，允许斯特雷克根据虚假索赔法的条款独立进行诉讼，该条款允许私人举报者提起诉讼。</p>
</div><p><strong>LLY Price Action:</strong> Eli Lilly ( LLY ) shares were down 1.64% at $988.42 at the time of publication on Monday, according to Benzinga Pro.</p>
<div class="lb-trans"><p><strong>LLY 价格动态：</strong> 根据 Benzinga Pro 的数据显示，礼来（LLY）股票在周一发布时下跌了 1.64%，报 988.42 美元。</p>
</div><p>Over the past month, Eli Lilly ( LLY ) stock has gained about 6.6% versus a 3.8% rise in the S&amp;P 500 and is down roughly 8% year-to-date compared to the index’s 7.3% gain.</p>
<div class="lb-trans"><p>在过去一个月中，礼来（LLY）股票上涨了约 6.6%，而标准普尔 500 指数上涨了 3.8%，与年初至今该股票下跌约 8% 相比，指数上涨了 7.3%。</p>
</div><p><em>Photo: Jonathan Weiss / Shutterstock</em></p>
<div class="lb-trans"><p><em>照片：Jonathan Weiss / Shutterstock</em></p>
</div><p><strong>Read Also: Ondas Bets Big On AI Battlefield Software With Omnisys Buyout</strong></p>
<div class="lb-trans"><p><strong>另请阅读：Ondas 在 Omnisys 收购中大举押注 AI 战场软件</strong></p>
</div>

最高法院驳回了礼来公司在医疗补助欺诈案中的上诉